Avapritinib Patent Expiration

Avapritinib is Used for treating advanced systemic mastocytosis, including aggressive types, and unresectable or metastatic gastrointestinal stromal tumors with a specific mutation. It was first introduced by Blueprint Medicines Corp in its drug Ayvakit on Jan 9, 2020.


Avapritinib Patents

Given below is the list of patents protecting Avapritinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ayvakit US12060354 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Mar 08, 2042 Blueprint Medicines
Ayvakit US11964980 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Apr 10, 2040 Blueprint Medicines
Ayvakit US11999744 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Apr 10, 2040 Blueprint Medicines
Ayvakit US11827642 Compositions useful for treating disorders related to KIT Oct 15, 2034 Blueprint Medicines
Ayvakit US9200002 Compositions useful for treating disorders related to KIT Oct 15, 2034 Blueprint Medicines
Ayvakit US9944651 Compositions useful for treating disorders related to kit Oct 15, 2034 Blueprint Medicines
Ayvakit US9994575 Compositions useful for treating disorders related to kit Oct 15, 2034 Blueprint Medicines



Avapritinib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List